<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529386</url>
  </required_header>
  <id_info>
    <org_study_id>BOTOX-CP</org_study_id>
    <nct_id>NCT00529386</nct_id>
  </id_info>
  <brief_title>Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)</brief_title>
  <official_title>A Prospective Pilot Study to Evaluate the Safety and Efficacy of Botox™ for the Treatment of Men Diagnosed With Chronic Prostatitis/Chronic Pelvic Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of intraprostatic
      injection of Botox for the treatment of men diagnosed with chronic nonbacterial
      prostatitis/chronic pelvic pain syndrome (CP/CPPS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective open label study examining the efficacy and safety of intraprostatic
      Botox . Men with a clinical diagnosis of chronic nonbacterial prostatitis/CPPS will be
      treated with intraprostatic Botox™ and followed for 12 weeks (primary efficacy analyses), and
      24 weeks (long term follow-up) for responders.

      It is proposed that a total of 40 males will be enrolled. There will be seven (7) research
      clinic visits and two phone contacts: Visit 1 (screening), Visit 2 (baseline/treatment),
      Visit 3 (2-week safety evaluation - clinic contact), Visit 4 (4-week safety evaluation -
      phone contact), Visit 5 (6-week interim efficacy/safety), Visit 6 (12-week primary endpoint
      evaluation), Visit 7 (14-week clinic follow up), Visit 8 (16 week phone contact) and Visit 9
      (24-week clinic close out).

      Outcome measures include Chronic Prostatitis Symptom Index (CPSI 0-35), NRS pain (0-10),
      Global Response Assessment (GRA) at 12 weeks. Safety to be monitored during the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GRA</measure>
    <time_frame>12 weeks</time_frame>
    <description>At 12 weeks there were no GRA responders. Study stopped because of futility.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Prostatitis</condition>
  <condition>Chronic Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Botox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 IU botox</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>300 units</description>
    <arm_group_label>Botox</arm_group_label>
    <other_name>Botulinem toxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant has signed and dated the appropriate Informed Consent document.

          2. Participant must be ≥ 18 years of age.

          3. Participant has had a clinical diagnosis of chronic nonbacterial prostatitis (chronic
             pelvic pain syndrome) (CPPS) defined as symptoms of discomfort or pain in the perineal
             or pelvic region for at least the past 3 months without evidence of bacterial
             infection.

          4. Participants must report ejaculatory pain and/or perineal discomfort.

          5. Participants must have pain or discomfort localized to perineum or prostate during
             physical examination.

          6. Participants must have an aggregate score of greater than or equal to 15 on the
             National Institutes of Health chronic prostatitis symptom index (NIH-CPSI).

          7. Participant must have &gt; 8 on the pain domain sub-score of the NIH-CPSI.

          8. Participant must have had empiric treatment with 4 weeks fluoroquinolone, and
             subsequently failed the antibiotic therapy.

        Exclusion Criteria:

          1. Participant has a history of prostate, bladder or urethral cancer.

          2. Participant has inflammatory bowel disease (such as Crohn's disease or ulcerative
             colitis, but not irritable bowel syndrome).

          3. Participant has undergone pelvic radiation or systemic chemotherapy.

          4. Participant has undergone intravesical chemotherapy.

          5. Participant has been treated for unilateral orchialgia without pelvic symptoms.

          6. Participant has a current urethral stricture and/or bladder stones.

          7. Participant has a neurological disease or disorder affecting the bladder.

          8. Participant has a neurological impairment or psychiatric disorder preventing his
             understanding of consent and his ability to comply with the protocol.

          9. Participant has a documented UTI within the last 3 months.

         10. Participant has evidence of facultative Gram negative or enterococcus with a value of
             ≥ 1000 CFU/ml in mid-stream urine (VB2).

         11. Participant has had previous intraprostatic injection of Botox.

         12. Participant currently enrolled in an investigational study.

         13. Participant interested in future fertility/fathering children.

         14. Participant with urinary retention (PVR &gt;200cc).

         15. Participant having had prostate surgery in the past 3 months.

         16. Participant having had minimally invasive surgical therapy for BPH.

         17. Participant with a cystostomy or nephrostomy.

         18. Participant with penile or urinary sphincter implants.

         19. Participant with previous rectal surgery, current rectal disease or peri-rectal
             inflammatory disorders except hemorrhoidectomy.

         20. Participant with PSA &gt;10 ng/ml(PSA range 4-10, biopsy at PI discretion (deferral).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Curtis Nickel, MD FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Advanced Urological Research</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>April 4, 2018</results_first_submitted>
  <results_first_submitted_qc>November 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2019</results_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. J. Curtis Nickel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>prostatitis</keyword>
  <keyword>Botox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatitis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Botox</title>
          <description>300 IU botox
Botox: 300 units</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7">Study has been discontinued</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6">Study discontinued after 7 patients enrolled and analyzed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Botox</title>
          <description>300 IU botox
Botox: 300 units</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>CPSI range for CP/CPPS</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GRA</title>
        <description>At 12 weeks there were no GRA responders. Study stopped because of futility.</description>
        <time_frame>12 weeks</time_frame>
        <population>7 CPCPPS patients enrolled and analysed before stopping study because of futility</population>
        <group_list>
          <group group_id="O1">
            <title>Botox</title>
            <description>300 IU botox
Botox: 300 units</description>
          </group>
        </group_list>
        <measure>
          <title>GRA</title>
          <description>At 12 weeks there were no GRA responders. Study stopped because of futility.</description>
          <population>7 CPCPPS patients enrolled and analysed before stopping study because of futility</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Botox</title>
          <description>300 IU botox
Botox: 300 units</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>J C Nickel</name_or_title>
      <organization>Dept of Urology, Queen's University</organization>
      <phone>613 548 2497</phone>
      <email>jcn@queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

